This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Dosing           DosingIBRANCE® Dosing
 
Monitoring Requirements
Safety            
SafetyIBRANCE® Safety ProfileNeutropeniaAdverse Event ManagementReal World EvidenceReal World EvidenceIBRANCE® Real World EvidenceIRIS (UK) StudyROIS
 
P-REALITY X

Menu

Close

Clinical Trials
Clinical TrialsIBRANCE® Clinical TrialsIBRANCE® PALOMA-2 Trial
 
IBRANCE® PALOMA-3 TrialPatient ProfilesThe Ibrance® PatientPatient ProfilesAllison - Postmenopausal with comorbiditiesBecky - Postmenopausal with bone-only diseaseELEVATE MasterclassSupport and ResourcesSupport and ResourcesIBRANCE Service SupportMaterials
 
Videos

The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics. IBRANCE® (palbociclib) Prescribing Information for the UK click here.  Adverse event reporting information can be found at the bottom of the page.

ePROMs: Electronic Patient-Reported Outcome MeasuresOncology services within NHS trusts continue to be overstretched by an influx of new treatments in both the advanced and adjuvant settings, which have prolonged survival rates and add to the capacity challenges faced by the NHS. ePROMs may offer a solution to help service providers manage these increasing patient numbers and workload demand.1
ePROMs are online questionnaires, completed by patients, to monitor any disease symptoms, adverse events of treatment, indicators of disease progression and physical function. They can offer a practical solution for patient support as part of a technology-enabled model of care.2
For more information on how to integrate ePROMs within your NHS trust, please download the resources below. These resources provide guidance on the three key phases of integrating ePROMs into patient care:
  1. Pre-implementation: Preparing your service and stakeholders
  2. Implementation: Effectively integrating ePROMs into your service with minimal disruption
  3. Post- implementation: Monitoring the impact of ePROMs and maintaining the smooth running of the service

Please see video above, which is a overview summary from Prof Galina Velikova on what ePROMs are and what these guides are aiming to support you with

These guides have been developed in collaboration with an NHS medical oncologist with extensive experience with ePROMs, Professor Galina Velikova from Leeds NHS THFT.

ePROMs summary Implementation GuideA concise step-by-step guide with case study examples to introduce and maintain ePROMs for oncology services in your NHS trust Click here to downloadLoadingePROMs detailed Implementation Guide

A detailed step-by-step guide with case study examples to introduce and maintain ePROMs for oncology services in your NHS trust

 Click here to downloadLoading

References

NHS. The NHS Long Term Plan. January 2019. Available at: www.longtermplan.nhs.uk/wp-content/uploads/2019/08/nhs-long-term-plan-version-1.2.pdf (accessed May 2023).
Shipman, L.A. and Faivre-Finn, C. (2021) '1748 Electronic Patient Reported Outcome Measures – next generation cancer patient monitoring?,' Abstracts, p. A475.2-A476. (Accessed January 2025).
PP-IBR-GBR-6332. April 2025

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2026 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

UNP-GBR-13934. January 2026
You are now leaving PfizerPro​​​​​
​
You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-GBR-12070. April 2025​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-13971. December 2025

YesNo
You are now leaving PfizerPro

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer's medicines or business which it has provided or reviewed.

PP-UNP-GBR-12107. April 2025
​​​​​​​